为了开发具有抗HFpEF功效的APLNR激动剂,进行多层次偏差化学空间改造
Qiu Sun1, Xiaowen Tian1, Lun Tan1
1Department of Cardiovascular Surgery, Cardiovascular Surgery Research Laboratory, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.
概括
研究人员通过准阿佩林受体 (APLNR) 来确定了用于心力衰竭的新药设计策略,其中包括保留喷射分数 (HFpEF). 这种方法增强了G蛋白偏差的激进作用,以获得更好的治疗效益.
科学领域:
- 心血管药理学心血管药理学
- G蛋白结合受体 (GPCR) 信号传递
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭是一个主要的健康问题,治疗选择有限.
- 阿佩林受体 (APLNR) 是HFpEF的潜在治疗标,受到其内源性连接体apelin的影响.
- 在APLNR中实现G蛋白偏差激进作用以获得治疗优势是具有挑战性的.
研究的目的:
- 为了研究部分Gi蛋白偏差APLNR激动剂CMF-019.19的偏差信号传导途径.
- 开发一种新的化学空间改造方法,用于识别专有的G蛋白偏差APLNR激动剂.
- 评估这些新型激动剂在HFpEF中的治疗潜力.
主要方法:
- 利用一个有偏见的化学空间改造策略来发现新的APLNR激动剂.
- 评估了已识别的激动剂的G蛋白偏差信号概况.
- 验证了这些激动剂在体外和体内模型中的有效性,这些模型与HFpEF相关.
主要成果:
- 成功识别了针对APLNR的专属G蛋白偏差激动剂.
- 这些新型激动剂显示了增强的Gi-蛋白偏差信号传递.
- 在体外和体外实验系统中表现出显著的保护作用.
结论:
- 这项研究增强了对APLNR偏差激发机制的理解.
- 建立了有效的药物设计策略,用于开发APLNR的偏向激动剂.
- 为治疗应用的其他GPCR目标重新塑造偏见的化学景观提供了一个框架.
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
2.5K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
2.5K
Structure-Activity Relationships and Drug Design
461
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
461
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
Drug-Receptor Interactions
4.7K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.7K
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K


